SIG 1311

Drug Profile

SIG 1311

Alternative Names: SIG-1311

Latest Information Update: 11 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Signum Biosciences
  • Developer Signum Dermalogix
  • Class Small molecules; Terpenes
  • Mechanism of Action G protein-coupled receptor modulators; Signal transduction pathway modulators; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis

Most Recent Events

  • 11 Aug 2016 Discontinued for Atopic dermatitis in USA (Topical)
  • 24 Sep 2010 Signum Biosciences receives two SBIR grants from the NIAMS for the development of GPCR modulating agents in Skin disorders.
  • 13 Jul 2010 Early research in Atopic dermatitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top